---
title: "AMAM.US (AMAM.US) — Related News"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/AMAM.US/news.md"
symbol: "AMAM.US"
name: "AMAM.US"
parent: "https://longbridge.com/en/quote/AMAM.US.md"
datetime: "2026-05-22T00:01:04.685Z"
locales:
  - [en](https://longbridge.com/en/quote/AMAM.US/news.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/AMAM.US/news.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/AMAM.US/news.md)
---

# AMAM.US (AMAM.US) — Related News

### [04:17 ETFapon Biopharma Presents at AACR Annual Meeting 2026, Showcasing Core Technology Platforms and Advancing Pipeline](https://longbridge.com/en/news/283316219.md)
*2026-04-20T08:18:59.000Z*
> Fapon Biopharma will present at the AACR Annual Meeting 2026 in San Diego, showcasing its innovative therapeutic antibod

### [Lytix Biopharma Grants Share Options to Board Member Under Incentive Plan](https://longbridge.com/en/news/282239732.md)
*2026-04-09T19:02:23.000Z*
> Lytix Biopharma Grants Share Options to Board Member Under Incentive Plan

### [Argent BioPharma Shareholders Back Capital Moves at General Meeting](https://longbridge.com/en/news/281963835.md)
*2026-04-08T02:58:33.000Z*
> Argent BioPharma Shareholders Back Capital Moves at General Meeting

### [Bora Biologics Successfully Completes 2,000L Engineering and Scale-Up Run in San Diego, Reinforcing Commercial-Scale Readiness](https://longbridge.com/en/news/281757479.md)
*2026-04-06T12:05:28.000Z*
> Bora Biologics has successfully completed its first 2,000-liter engineering and scale-up run at its FDA-approved facilit

### [Xbrane Sets April–May Target to Resubmit Ranibizumab Biosimilar BLA to U.S. FDA](https://longbridge.com/en/news/281254166.md)
*2026-03-31T21:49:20.000Z*
> Xbrane Sets April–May Target to Resubmit Ranibizumab Biosimilar BLA to U.S. FDA

### [Can-Fite Reports 2025 Financial Results and Ongoing Clinical Progress Highlighting Positive Data in Phase 2a Pancreatic cancer and 9 Years Cancer-Free Survival in Liver Cancer Patient | CANF Stock News](https://longbridge.com/en/news/280640690.md)
*2026-03-26T05:31:13.000Z*
> Can-Fite Reports 2025 Financial Results and Ongoing Clinical Progress Highlighting Positive Data in Phase 2a Pancreatic 

### [Lytix Biopharma Calls April AGM and Proposes No 2025 Dividend](https://longbridge.com/en/news/280438130.md)
*2026-03-25T08:33:35.000Z*
> Lytix Biopharma Calls April AGM and Proposes No 2025 Dividend

### [Lytix Biopharma Marks Pivotal 2025 With Strong Melanoma Data and Capital Raise](https://longbridge.com/en/news/280270239.md)
*2026-03-24T07:02:40.000Z*
> Lytix Biopharma Marks Pivotal 2025 With Strong Melanoma Data and Capital Raise